New study reveals how MS drug enters breast milk
NCT ID NCT06444113
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 26 times
Summary
This study looks at how much of the multiple sclerosis (MS) drug ofatumumab gets into breast milk. About 24 breastfeeding women with relapsing MS will provide milk samples after starting or restarting the drug. The goal is to help mothers and doctors understand the safety of breastfeeding while on this medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Womens Hospital
Brookline, Massachusetts, 02445, United States
-
Northwestern Medicine Northwestern University
Winfield, Illinois, 60190, United States
-
Novartis Investigative Site
Munich, Bavaria, 81377, Germany
-
Novartis Investigative Site
Bochum, 44791, Germany
-
Novartis Investigative Site
Hamburg, 22179, Germany
-
Novartis Investigative Site
Tübingen, 72076, Germany
-
Novartis Investigative Site
Foggia, FG, 71122, Italy
-
Novartis Investigative Site
Bialystok, 15 276, Poland
-
Novartis Investigative Site
Kielce, 25 726, Poland
-
Novartis Investigative Site
Cambridge, CB2 0QQ, United Kingdom
-
Novartis Investigative Site
London, NW1 2BU, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 9DU, United Kingdom
-
Novartis Investigative Site
Salford, M6 8HD, United Kingdom
-
UC Health Neuroscience Ctr
Aurora, Colorado, 80045, United States
-
UCSF
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.